IMVT.US Immunovant Inc

Healthcare Biotechnology USA Stocks
34.18 USD
Close of Nov 15, 2026
21.86 45.42
Market cap
USD 7.07B
P/E
-
P/B
10.77x
ROE
-76.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is IMVT.US undervalued?

Graham number

The Graham number of Immunovant Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immunovant Inc fundamental analysis

No fundamental analysis for Immunovant Inc yet.

Immunovant Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immunovant Inc

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, Nort…

Full company profile